Výsledky vyhledávání - "Duncan K. Wilkins"

Autor: Richard H. J. Begent, Duncan K. Wilkins

Publikováno v: The Cancer Handbook

Systemic cytotoxic chemotherapy has beneﬁted manypatients with haematological and solid tumours. However,the success of cytotoxic drugs is hampered by their tox-icity to non-tumour tissue. The relative non-selectivity ofconventional chemotherapy li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ede41f620495dce432779a633b1dca06
https://doi.org/10.1002/9780470025079.chap87.pub2

Zobrazit plný text záznamu

Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer

Autor: Ruth Plummer, Donna Crawford, Richard A Cowan, Duncan K. Wilkins, Balaji Venugopal, Fiona MacCormick, Jeff Evans, Udai Banerji, Yusri Elsayed, Nele Fourneau, Rebecca Kristeleit, Roberta Granata, John Camm, Johann S. de Bono, Richard D. Baird, Julie Charlton, Peter Hellemans

Publikováno v: Molecular Cancer Therapeutics. 10:A164-A164

Background: HDACi have demonstrated activity as anticancer agents and are licensed for use in cutaneous and peripheral T cell lymphoma. Cardiac effects including arrhythmias and QTc prolongation have previously been associated with HDACi administrati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32aa6393a7ffad8c32375eb25b91b2d6
https://doi.org/10.1158/1535-7163.targ-11-a164

Zobrazit plný text záznamu

Abstract LB-200: Evidence of efficacy of antibody directed enzyme prodrug therapy (ADEPT) in a Phase I trial in patients with advanced carcinoma

Autor: Jimmy D. Bell, A Mayer, Geoff Boxer, Berend Tolner, Sweta Parker, Caroline J. Springer, Natalie Griffin, Richard H. J. Begent, Edward Grudus, Hassan Shahbakhti, Surinder K. Sharma, Duncan K. Wilkins, Kerry A. Chester, A J Green, R. J. Francis, Janet A Hartley

Publikováno v: Cancer Research. 68:LB-200

Background: Antibody Directed Enzyme Prodrug Therapy (ADEPT) uses an antibody linked to an enzyme to deliver enzyme selectively to tumor deposits. When enzyme has localized to the tumor and cleared from the circulation, a low-toxicity prodrug is give

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c6764f0eb0169b6cbd03c94089ee6fe
https://doi.org/10.1158/1538-7445.am2008-lb-200

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání